First Description of Late ‐Onset Autoinflammatory Disease Due to Somatic NLRC4 Mosaicism

ConclusionWe have identified the post-zygotic p.Ser171Phe NLRC4 variant as a plausible cause of the disease in the enrolled patient. Functional and structural studies clearly support for the first time itsgain-of-function behavior consistent with previously reported NLRC4 pathogenic variants. These novel evidences should be considered in the diagnostic workup of patients with uncharacterized AID starting during adulthood.
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: BRIEF REPORT Source Type: research

Related Links:

Cooled radiofrequency (RF) ablation procedures can relieve pain that persist...Read more on AuntMinnie.comRelated Reading: Can AI help improve racial disparities in healthcare? Limiting x-rays after knee replacement could save millions of dollars Outpatient radiology procedure offers arthritis relief AI model predicts need for total knee replacement 3D-printed device aids knee replacement surgery
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Purpose of review To provide an overview of the recent research publications on educational needs of patients with psoriatic arthritis (PsA) and the associated challenges. Recent findings The rate of good treatment adherence in PsA can be as low as 57.7% and successful patient education can help improve treatment adherence. Also, 78.7% of patients who stopped their disease modifying anti-rheumatic drugs during the first wave of the COVID-19 pandemic did so without the advice of their clinician. In delivering educational needs, the aspects of disease process, treatment, self-help measures, managing pain, movement...
Source: Current Opinion in Rheumatology - Category: Rheumatology Tags: SPONDYLOARTHROPATHIES INCLUDING PSORIATIC ARTHRITIS: Edited by Joerg Ermann Source Type: research
Having trouble viewing this email? View it as a Web page. NIDCR's Spring 2021 E-Newsletter In this issue: NIDCR News Funding Opportunities &Related Notices NIH/HHS News Subscribe to NICDR News Science Advances   Grantee News   NIDCR News NIDCR &NIH Stand Against Structural Racism NIDCR Director Rena D’Souza, DDS, MS, PhD, said in a statement that there is no place for structural racism in biomedical research, echoing remarks from NIH Director Francis Collins, MD, PhD, in his announcement of a new NIH in...
Source: NIDCR Science News - Category: Dentistry Source Type: news
Having trouble viewing this email? View it as a Web page. NIDCR's Winter 2020 E-Newsletter In this issue: NIDCR News Funding Opportunities NIH/HHS News Funding Notices Science Advances Subscribe to NICDR News Grantee News   NIDCR News NIDCR Welcomes New Director Rena D’Souza Rena N. D’Souza, DDS, MS, PhD, was sworn in as the director of NIDCR by NIH Director Francis S. Collins, MD, PhD, on October 13. Prior to joining NIH, Dr. D’Souza was the assistant vice president for academic affairs and education for health s...
Source: NIDCR Science News - Category: Dentistry Source Type: news
CONCLUSION: The Spanish and French versions of SEFAS are valid, reliable instruments for evaluating foot and ankle pain and function. IMPLICATIONS FOR REHABILITATION Self-report questionnaires specific to patients with rheumatoid arthritis are needed to assess the degree of pain, disability, and disability caused by foot problems. The Spanish and French versions of SEFAS show the necessary psychometric characteristics. Each version provides a valid, reliable tool ensuring the correct evaluation of pain, function and limitation of function in the foot and/or ankle in the target population. PMID: 33228426 [PubMed - as s...
Source: Disability and Rehabilitation - Category: Rehabilitation Authors: Tags: Disabil Rehabil Source Type: research
Here’s a recent headline that I found confusing: Could the first drug that slows arthritis be here? It’s confusing because it depends on which of the more than 100 types of arthritis we’re discussing. We’ve had drugs that slow rheumatoid arthritis for decades. In fact, more than a dozen FDA-approved drugs can reduce, or even halt, joint damage in people with rheumatoid arthritis. We also have effective medications to slow or stop gout, another common type of arthritis. But the headline refers to osteoarthritis, the most common type of arthritis. And currently, no medications can safely and reliably ...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Arthritis Health Inflammation Source Type: blogs
ConclusionThis study has identified a number of components of the pain flare experience. Findings show that pain flares are more than an increase in pain intensity; they are multi ‐layered and require other features to change. These findings help to differentiate pain flares from typical fluctuations in pain.
Source: European Journal of Pain - Category: Anesthesiology Authors: Tags: ORIGINAL ARTICLE Source Type: research
ConclusionThis study has identified a number of components of the pain flare experience. Findings show that pain flares are more than an increase in pain intensity; they are multi ‐layered and require other features to change. These findings help to differentiate pain flares from typical fluctuations in pain.
Source: European Journal of Pain - Category: Anesthesiology Authors: Tags: ORIGINAL ARTICLE Source Type: research
​We discussed the initial approach to the red, hot swollen wrist joint last month, and this month we focus on arthrocentesis of the joint with a full video of the procedure, including ultrasound and joint aspiration.A swollen, painful wrist that is hot to the touch with scant erythema is concerning for septic arthritis. The patient had multiple Band-Aids on his fingertips from blood glucose testing for diabetes, which increased his chances of having a septic joint with the punctures serving as an entry site for infection. Photo by Martha Roberts.The ProcedureIdentify the swollen joint, review the differential diagnosis, ...
Source: The Procedural Pause - Category: Emergency Medicine Tags: Blog Posts Source Type: blogs
In early April, about four months after a new, highly infectious coronavirus was first identified in China, an international group of scientists reported encouraging results from a study of an experimental drug for treating the viral disease known as COVID-19. It was a small study, reported in the New England Journal of Medicine, but showed that remdesivir, an unapproved drug that was originally developed to fight Ebola, helped 68% of patients with severe breathing problems due to COVID-19 to improve; 60% of those who relied on a ventilator to breathe and took the drug were able to wean themselves off the machines after 18...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
More News: Arthritis | Genetics | HIV AIDS | Men | Pain | Rheumatology | Study